CLINICAL_TRIALS ClinicalTrials.gov record update

Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04635956
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:56.042003+00:00
Published At: 2020-11-19T00:00:00+00:00
Record Updated At: 2020-11-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Chemotherapy", "Anti-pd-1 Antibody", "Cervical Neuroendocrine Carcinoma", "Adverse Drug Event", "Recurrent Cervical Carcinoma", "Advanced Cervical Carcinoma", "Objective Response Rate"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-11-19"
protocolSection.identificationModule.nctId: "NCT04635956"
protocolSection.identificationModule.officialTitle: "Anti-PD-1 Antibody Camrelizumab Combined With Cisplatin/Paclitaxel/Bevacizumab for Recurrent or Advanced Cervical Neuroendocrine Carcinomas: A Single Arm, Phase II Trial"
protocolSection.statusModule.overallStatus: "UNKNOWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.